TY - JOUR
T1 - Safety and efficacy of cryoballoon ablation for the treatment of atrial fibrillation in diabetic patients
AU - Abdin, Amr
AU - Heeger, Christian H.
AU - Yalin, Kivanc
AU - Santoro, Francesco
AU - Brunetti, Natale Daniele
AU - Fink, Thomas
AU - Liosis, Spyridon
AU - Brueggemann, Ben
AU - Keelani, Ahmad
AU - Phan, Huong Lan
AU - Sano, Makoto
AU - Sciacca, Vanessa
AU - Lyan, Evgeny
AU - An, Dong
AU - Meyer-Saraei, Roza
AU - Ouyang, Feifan
AU - Kuck, Karl Heinz
AU - Eitel, Charlotte
AU - Vogler, Julia
AU - Tilz, Roland Richard
N1 - Funding Information:
CHH received travel grants and research grants by Medtronic, Pfizer, Novartis, Claret Medical, SentreHeart, Biosense Webster, Boston Scientific and Cardiofocus. He received speaker’s honoraria from Cardiofocus, Boston Scientific and Novartis. RRT received travel grants from St. Jude Medical, Topera, Biosense Webster, Daiichi Sankyo, SentreHeart and speaker’s honoraria from Biosense Webster, Biotronik, Pfizer, Topera, Bristol-Myers Squibb; Bayer, Sano Aventis and research grants by Cardiofocus. CE received travel grants and educational grants by Medtronic. KHK received travel grants and research grants from Biosense Webster, Stereotaxis, Prorhythm, Medtronic, Edwards, Cryocath, and is a consultant to St. Jude Medical, Biosense Webster, Prorhythm, and Stereotaxis. He received speaker’s honoraria from Medtronic. All other authors have no relevant disclosures.
Publisher Copyright:
© 2020 CardioFront LLC. All rights reserved.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020
Y1 - 2020
N2 - Background: Cryoballoon based catheter ablation (CB-CA) is an established therapy for treatment of symptomatic atrial fibrillation (AF). However, data about AF ablation using the CB in the diabetic population is sparse. The aim of this single center retrospective study is to evaluate the safety and efficacy of CB ablation in patients with diabetes mellitus (DM) as compared to patients without DM. Methods and results: Between July 2015 and December 2017, 397 consecutive patients underwent CB-CA for AF. Forty-eight consecutive patients with DM (DM group, study group) were compared with propensity score-matched patients without DM (n=48, control group). All patients underwent pulmonary vein isolation (PVI) using the second-generation CB (CB2). The mean age in the DM group was 66.9±9.5 years and 69.5±8.8 in the non-DM group (p=0.18). During a follow-up of 12.7±5.1 months, single procedure success rate for the DM and the non-DM group was 68.7% and 70.8%, respectively (p=0.82). The most common complication was transient phrenic nerve palsy (4 DM group vs. 0 non-DM group, p=0.04). No severe complication such as procedure related deaths, atrio-esophageal fistula or cerebrovascular embolic events occurred. Conclusions: Our data strengthen the value of CB2 based ablation for the treatment of AF as an effective and safe procedure in DM patients, with similar success rates when compared with a non-DM population.
AB - Background: Cryoballoon based catheter ablation (CB-CA) is an established therapy for treatment of symptomatic atrial fibrillation (AF). However, data about AF ablation using the CB in the diabetic population is sparse. The aim of this single center retrospective study is to evaluate the safety and efficacy of CB ablation in patients with diabetes mellitus (DM) as compared to patients without DM. Methods and results: Between July 2015 and December 2017, 397 consecutive patients underwent CB-CA for AF. Forty-eight consecutive patients with DM (DM group, study group) were compared with propensity score-matched patients without DM (n=48, control group). All patients underwent pulmonary vein isolation (PVI) using the second-generation CB (CB2). The mean age in the DM group was 66.9±9.5 years and 69.5±8.8 in the non-DM group (p=0.18). During a follow-up of 12.7±5.1 months, single procedure success rate for the DM and the non-DM group was 68.7% and 70.8%, respectively (p=0.82). The most common complication was transient phrenic nerve palsy (4 DM group vs. 0 non-DM group, p=0.04). No severe complication such as procedure related deaths, atrio-esophageal fistula or cerebrovascular embolic events occurred. Conclusions: Our data strengthen the value of CB2 based ablation for the treatment of AF as an effective and safe procedure in DM patients, with similar success rates when compared with a non-DM population.
UR - http://www.scopus.com/inward/record.url?scp=85095770860&partnerID=8YFLogxK
U2 - 10.4022/JAFIB.2285
DO - 10.4022/JAFIB.2285
M3 - Journal articles
AN - SCOPUS:85095770860
SN - 1941-6911
VL - 12
JO - Journal of Atrial Fibrillation
JF - Journal of Atrial Fibrillation
IS - 6
ER -
